SG11201907391SA - Novel vegfr-2 targeting immunotherapy approach - Google Patents

Novel vegfr-2 targeting immunotherapy approach

Info

Publication number
SG11201907391SA
SG11201907391SA SG11201907391SA SG11201907391SA SG11201907391SA SG 11201907391S A SG11201907391S A SG 11201907391SA SG 11201907391S A SG11201907391S A SG 11201907391SA SG 11201907391S A SG11201907391S A SG 11201907391SA SG 11201907391S A SG11201907391S A SG 11201907391SA
Authority
SG
Singapore
Prior art keywords
cancer
cwwg
receptor protein
international
vegf receptor
Prior art date
Application number
SG11201907391SA
Other languages
English (en)
Inventor
Heinz Lubenau
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of SG11201907391SA publication Critical patent/SG11201907391SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/423—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201907391SA 2017-02-17 2018-02-16 Novel vegfr-2 targeting immunotherapy approach SG11201907391SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17156718 2017-02-17
PCT/EP2018/053918 WO2018149982A1 (en) 2017-02-17 2018-02-16 Novel vegfr-2 targeting immunotherapy approach

Publications (1)

Publication Number Publication Date
SG11201907391SA true SG11201907391SA (en) 2019-09-27

Family

ID=58094260

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907391SA SG11201907391SA (en) 2017-02-17 2018-02-16 Novel vegfr-2 targeting immunotherapy approach

Country Status (13)

Country Link
US (1) US10980868B2 (enExample)
EP (1) EP3583200A1 (enExample)
JP (2) JP7712060B2 (enExample)
KR (2) KR20190117603A (enExample)
CN (1) CN110291187A (enExample)
AU (1) AU2018222777B9 (enExample)
BR (1) BR112019016925A2 (enExample)
CA (1) CA3050833A1 (enExample)
IL (1) IL268186A (enExample)
MX (1) MX2019009724A (enExample)
RU (1) RU2019125436A (enExample)
SG (1) SG11201907391SA (enExample)
WO (1) WO2018149982A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250024816A (ko) * 2015-06-18 2025-02-19 백심 아게 병용 요법을 위한 vegfr-2 표적화 dna 백신
US20210213121A1 (en) * 2018-09-05 2021-07-15 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
AU2021208400A1 (en) * 2020-01-13 2022-08-11 Vaximm Ag Salmonella-based DNA vaccines in combination with an antibiotic
CN113527509B (zh) * 2020-04-17 2023-09-26 深圳华大生命科学研究院 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
BR112014015706A2 (pt) * 2011-12-22 2020-10-27 Vaximm Ag método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a
SG11201500054QA (en) * 2012-07-05 2015-03-30 Vaximm Ag Dna vaccine for use in pancreatic cancer patients
DK2988762T3 (en) * 2013-04-25 2018-07-16 Vaximm Ag SALMONELLA-BASED VECTORS FOR CANCER IMMUNITY TARGET TARGETED WILMS 'TUMORGEN WT1
PL3082850T3 (pl) * 2013-12-18 2020-01-31 Vaximm Gmbh Celowana szczepionka DNA MSLN w immunoterapii nowotworu
WO2015142875A1 (en) * 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods using modified salmonella
KR20250024816A (ko) * 2015-06-18 2025-02-19 백심 아게 병용 요법을 위한 vegfr-2 표적화 dna 백신
AU2017295004B2 (en) * 2016-07-13 2020-08-13 NEC Oncolmmunity AS Process for the production of a DNA vaccine for cancer immunotherapy

Also Published As

Publication number Publication date
AU2018222777B2 (en) 2024-02-01
CA3050833A1 (en) 2018-08-23
JP2020507332A (ja) 2020-03-12
MX2019009724A (es) 2019-10-07
RU2019125436A (ru) 2021-03-17
AU2018222777A1 (en) 2019-08-08
BR112019016925A2 (pt) 2020-05-26
KR20240170928A (ko) 2024-12-05
JP7712060B2 (ja) 2025-07-23
IL268186A (en) 2019-09-26
KR20190117603A (ko) 2019-10-16
AU2018222777B9 (en) 2024-02-22
EP3583200A1 (en) 2019-12-25
WO2018149982A1 (en) 2018-08-23
US10980868B2 (en) 2021-04-20
CN110291187A (zh) 2019-09-27
US20200038496A1 (en) 2020-02-06
JP2023160838A (ja) 2023-11-02

Similar Documents

Publication Publication Date Title
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201900468YA (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
SG11201907846VA (en) Therapeutic rna
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201808196UA (en) Neoantigens and methods of their use
SG11201909777YA (en) Modulatory polynucleotides
SG11201909868YA (en) Compositions and methods of treating huntington's disease
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201407972RA (en) High-affinity monoclonal antibodies to glypican-3 and use thereof
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201407508RA (en) Encoding and decoding based on blending of sequences of samples along time
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201805072PA (en) Nicotine powder delivery system
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808176TA (en) Gene therapy for treating mucopolysaccharidosis type ii
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201806261XA (en) Bcma antibodies and use of same to treat cancer and immunological disorders
SG11201808125RA (en) Methods for solid tumor treatment
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex